Relevant Publications for Soligenix, a biopharmaceutical company developing Vaccines & BioDefense products

  • Wednesday, May 8th, 2019
    Dr. Christopher J. Schaber’s Interview with The Wall Street Analyzer

    In this interview, Dr. Christopher J. Schaber, President and CEO, discusses the Company with The Wall Street Analyzer.

    Listen to the interview (opens in a new window)

    Continue reading →
  • Tuesday, December 4th, 2018
    Article in Drug Target Review

    In this article in Drug Target Review, Drs. Donini, Schaber, and Straube discuss innate immunity. To read the article, click here.

    Continue reading →
  • Monday, November 5th, 2018
    Dr. Oreola Donini’s Interview with Nature

    In this interview, Dr. Oreola Donini, Senior Vice President and Chief Scientific Officer, discusses innate immunity and development of Innate Defense Regulator technology with Nature. To read the article, click here.

    Continue reading →
  • Thursday, October 4th, 2018
    Soligenix Discusses Ricin Toxin Vaccine

    Dr. Oreola Donini, Senior Vice President and Chief Scientific Officer, discusses the Company’s ricin toxin vaccine with ROI-NJ. To read the article please click here.

    Continue reading →
  • Thursday, May 18th, 2017
    Biotechnology Reports – Dusquetide: Reduction in Oral Mucositis associated with Enduring Ancillary Benefits in Tumor Resolution and Decreased Mortality in Head and Neck Cancer Patients
  • Thursday, April 27th, 2017
    BioWorld Today Ricin Toxin Program Review

    In a recent article in BioWorld Today, the Soligenix ricin toxin vaccine program was reviewed, including comments from Dr. Oreola Donini, Chief Scientific Officer of Soligenix.

    View the article here.

    Continue reading →
  • Wednesday, October 19th, 2016
    Journal of Biotechnology – Dusquetide: A Novel Innate Defense Regulator Demonstrating a Significant and Consistent Reduction in the Duration of Oral Mucositis in Preclinical Data and a Randomized, Placebo-Controlled Phase 2a Clinical Study

    The publication of positive clinical results consistent with preclinical data

    Read the publication (pdf)

    Continue reading →
  • Tuesday, May 10th, 2016
    Soligenix on IDR technology and SGX942

    Dr. Oreola Donini, Chief Scientific Officer of Soligenix, Inc. recently discussed the IDR technology and SGX942 with two publications.

    Read the article in European Pharmaceutical Review

    Read the article in Drug Target Review

    Continue reading →
  • Friday, April 29th, 2016
    Journal of Biotechnology – A novel approach for emerging and antibiotic resistant infections: Innate defense regulators as an agnostic therapy

    The publication of data demonstrating the mechanism and broad-spectrum activity of dusquetide in preclinical bacterial infection models

    Read the publication (pdf)

    Continue reading →
  • Wednesday, October 28th, 2015
    NJBIZ – Impacting the world: Soligenix discovery could dramatically change vaccinations

    Dr. Christopher J. Schaber, President & CEO discusses ThermoVax™ technology and the vaccine market
    Read the article

    Continue reading →
  • Monday, September 14th, 2015
    Scientia – Innate Defense Regulators: Novel Therapeutics for Emerging and Antibiotic-Resistant Diseases

    Dr. Oreola Donini, Chief Scientific Officer discusses SGX94
    Read the publication (pdf)

    Continue reading →
  • Friday, September 11th, 2015
    Drug Discovery News: On The Front Lines of Biodefense

    Q&A with Dr. Christopher J. Schaber, President & CEO
    Read the publication (pdf)

    Continue reading →
  • Tuesday, August 11th, 2015
    International Innovation – Bullseye: Targeting Cancer with Selective Innovations, Issue 190

    Drs. Schaber and Straube Discuss Treatment of Cutaneous T-Cell Lymphoma in Recent Publication
    Read the publication (pdf)

    Continue reading →
  • Sunday, August 2nd, 2015
    Soligenix Aims to Improve Quality of Life for Patients with Cutaneous Lymphoma

    Freelance author discusses SGX301 and CTCL on LymphomaInfo.net
    Read the article

    Continue reading →

Try to ensure there will be no hidden costs that might sometimes be imposed by certain companies, such as the fees for some additional services or some other extra expenses. This will allow you to be fully confident that you will not have to pay any extra cash. The above-mentioned points indicate that there are many risks associated with purchasing drugs from online companies, although it still remains a highly convenient way to get what you need timely and without unwanted trouble. Additional Facts about Buying Drugs from canadianrxantibiotics.com Online Above all, you should ensure that you are guaranteed timely delivery, especially if you need your drugs to be delivered to you as soon as possible. Sometimes, there might be certain restrictions imposed by the border protection services, which might result in the untimely delivery of your drugs. Nevertheless, it is always better to take the necessary precautions in advance by contacting the company whose services you are using and letting them know that you need to get your medications without delays. This is especially vital if you have never used the services of the chosen drugstore before and do not know much about their reliability.